Calvin N Leung1, Brian S Canter1,2, Didier Rajon3, Tom A Bäck4, J Christopher Fritton2, Edouard I Azzam1, Roger W Howell5. 1. Department of Radiology, New Jersey Medical School, Rutgers University, Newark, New Jersey. 2. Department of Orthopedics, New Jersey Medical School, Rutgers University, Newark, New Jersey. 3. Department of Neurosurgery, University of Florida, Gainesville, Florida; and. 4. Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 5. Department of Radiology, New Jersey Medical School, Rutgers University, Newark, New Jersey rhowell@rutgers.edu.
Abstract
The role of radiation-induced bystander effects in radiation therapy remains unclear. With renewed interest in therapy with α-particle emitters, and their potential for sterilizing disseminated tumor cells (DTCs), it is critical to determine the contribution of bystander effects to the overall response so they can be leveraged for maximum clinical benefit. Methods: Female Foxn1nu athymic nude mice were administered 0, 50, or 600 kBq/kg 223RaCl2 to create bystander conditions. At 24 hours after administration, MDA-MB-231 or MCF-7 human breast cancer cells expressing luciferase were injected into the tibial marrow compartment. Tumor burden was tracked weekly via bioluminescence. Results: The MDA-MB-231 xenografts were observed to have a 10-day growth delay in the 600 kBq/kg treatment group only. In contrast, MCF-7 cells had 7- and 65-day growth delays in the 50 and 600 kBq/kg groups, respectively. Histologic imaging of the tibial marrow compartment, α-camera imaging, and Monte Carlo dosimetry modeling revealed DTCs both within and beyond the range of the α-particles emitted from 223Ra in bone for both MCF-7 and MDA-MB-231 cells. Conclusion: Taken together, these results support the participation of 223Ra-induced antiproliferative/cytotoxic bystander effects in delayed growth of DTC xenografts. They indicate that the delay depends on the injected activity and therefore is dose-dependent. They suggest using 223RaCl2 as an adjuvant treatment for select patients at early stages of breast cancer.
The role of radiation-induced bystander effects in radiation therapy remains unclear. With renewed interest in therapy with α-particle emitters, and their potential for sterilizing disseminated tumor cells (DTCs), it is critical to determine the contribution of bystander effects to the overall response so they can be leveraged for maximum clinical benefit. Methods: Female Foxn1nu athymic nude mice were administered 0, 50, or 600 kBq/kg 223RaCl2 to create bystander conditions. At 24 hours after administration, MDA-MB-231 or MCF-7 humanbreast cancer cells expressing luciferase were injected into the tibial marrow compartment. Tumor burden was tracked weekly via bioluminescence. Results: The MDA-MB-231 xenografts were observed to have a 10-day growth delay in the 600 kBq/kg treatment group only. In contrast, MCF-7 cells had 7- and 65-day growth delays in the 50 and 600 kBq/kg groups, respectively. Histologic imaging of the tibial marrow compartment, α-camera imaging, and Monte Carlo dosimetry modeling revealed DTCs both within and beyond the range of the α-particles emitted from 223Ra in bone for both MCF-7 and MDA-MB-231 cells. Conclusion: Taken together, these results support the participation of 223Ra-induced antiproliferative/cytotoxic bystander effects in delayed growth of DTC xenografts. They indicate that the delay depends on the injected activity and therefore is dose-dependent. They suggest using 223RaCl2 as an adjuvant treatment for select patients at early stages of breast cancer.
Authors: Brenda E Pratt; Cecilia Hindorf; Sarah J Chittenden; Christopher C Parker; Glenn D Flux Journal: Nucl Med Commun Date: 2018-02 Impact factor: 1.690
Authors: Stephan Braun; Florian D Vogl; Bjørn Naume; Wolfgang Janni; Michael P Osborne; R Charles Coombes; Günter Schlimok; Ingo J Diel; Bernd Gerber; Gerhard Gebauer; Jean-Yves Pierga; Christian Marth; Daniel Oruzio; Gro Wiedswang; Erich-Franz Solomayer; Günther Kundt; Barbara Strobl; Tanja Fehm; George Y C Wong; Judith Bliss; Anne Vincent-Salomon; Klaus Pantel Journal: N Engl J Med Date: 2005-08-25 Impact factor: 91.245
Authors: Brian S Canter; Calvin N Leung; J Christopher Fritton; Tom Bäck; Didier Rajon; Edouard I Azzam; Roger W Howell Journal: Mol Cancer Res Date: 2021-05-26 Impact factor: 5.852
Authors: Didier A Rajon; Brian S Canter; Calvin N Leung; Tom A Bäck; J Christopher Fritton; Edouard I Azzam; Roger W Howell Journal: Int J Radiat Biol Date: 2021-07-26 Impact factor: 3.352